Opthea (OPT) Announces Executive Changes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Opthea Announces Executive Leadership Changes and Senior Hires
September 5, 2024 6:00 AM EDTDaniel Geffken appointed Chief Financial Officer ad interim
Mike Campbell appointed Chief Commercial Officer
Three senior leaders appointed for Biometrics, Clinical Operations and Market Access
MELBOURNE, Australia and PRINCETON, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, Opthea, the Company), a clinical-stage biopharmaceutical Company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced executive leadership changes in Commercial and Finance as well as senior hires for Biometrics, Clinical Operations and Market... More
